Biomarker study of immunological response in Japanese patients with stage III non-small cell lung cancer receiving chemoradiotherapy followed by durvalumab

Biomarker study of immunological response in Japanese patients with stage III non-small cell lung cancer receiving chemoradiotherapy followed by durvalumab - Dual-Bio study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039167

Enrollment

150

Registered

2020-01-16

Start date

2020-02-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmed non-small cell lung cancer 2) Clinical stage III (8th TNM) including recurrence after surgery 3) Planned to receive chemoradiotherapy with latinum agent 4) Planned to receive durvalumab as consolidation 5) Age >=20 years 6) Written informed consent

Exclusion criteria

Exclusion criteria: 1) previously treated with PD-1/PD-L1 inhibitors or anti CTLA-4 antibody

Design outcomes

Primary

Measure	Time frame
1) Association between survival and immunological factors in PBMC 2) Association between toxicities and immunological factors in PBMC 3) Association between the efficacy of durvalumab and immunological factors in PBMC 4) Association between the efficacy of durvalumab and proteome analysis	—

Countries

Japan

Contacts

Public ContactHirotsugu Kemmotsu

Shizuoka Cancer Center Division of Thoracic Oncology

h.kenmotsu@scchr.jp055-989-5222

Outcome results